UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K
 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 19, 2015
 

PHARMERICA CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
 
 
Delaware
 
001-33380
 
87-0792558
(State or Other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
1901 Campus Place
Louisville, Kentucky 40299
(Address of principal executive offices) (Zip Code)
 
(502) 627-7000
(Registrant’s telephone number, including area code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2015 Annual Meeting of Stockholders of PharMerica Corporation (the “Company”) was held on June 19, 2015.
 
1.
The Company’s stockholders approved the election of the following nine directors for a term to expire at the Annual Meeting of Stockholders in 2016. The votes for each director were as follows:
 
Name
  
For
    
Withheld Authority
    
Broker Non-Votes
  
Frank E. Collins, Esq.
    
26,312,400
      
425,029
      
2,227,397
  
W. Robert Dahl, Jr.
    
26,541,693
      
195,736
      
2,227,397
  
Marjorie W. Dorr
    
26,545,191
      
192,238
      
2,227,397
  
Thomas P. Gerrity, Ph.D.
    
26,316,311
      
421,118
      
2,227,397
  
Patrick G. LePore
    
26,539,421
      
198,008
      
2,227,397
  
Thomas P. Mac Mahon
    
26,539,090
      
198,339
      
2,227,397
  
Geoffrey G. Meyers
    
26,318,584
      
418,845
      
2,227,397
  
Robert A. Oakley, Ph.D.
    
26,541,020
      
196,409
      
2,227,397
  
Gregory S. Weishar
    
25,539,361
      
198,068
      
2,227,397
  
 
2.
The Company’s stockholders voted upon the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015. The votes on this proposal were as follows:
 
For
  
Against
  
Abstained
28,879,980   75,422   9,424
 
3.
The Company’s stockholders voted upon and approved, by advisory vote, the compensation of the Company’s named executive officers. The votes on this proposal were as follows:
 
For
  
Against
  
Abstained
  
Broker Non-Votes
24,801,009
  
1,703,482
  
232,938
  
2,227,397

4.
The Company’s stockholders voted upon and approved and adopted the PharMerica Corporation 2015 Omnibus Incentive Plan. The votes on this proposal were as follows:
 
For
  
Against
  
Abstained
  
Broker Non-Votes
23,399,246
  
3,221,514
  
116,669
  
2,227,397

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PHARMERICA CORPORATION
     
Date: June 23, 2015
By:
 
/s/ Thomas A. Caneris
   
 
Thomas A. Caneris
   
 
Senior Vice President, General Counsel, Chief
Compliance Officer, and Secretary